0000000000144576

AUTHOR

Filippo Alongi

0000-0002-6569-8628

showing 26 related works from this author

Spinal metastases: Is stereotactic body radiation therapy supported by evidences?

2016

Stereotactic body radiotherapy (SBRT) is becoming widely adopted in the treatment of primary and secondary tumors. Spinal bone metastases are frequently discovered in cancer patients, and in the past have been usually treated with a palliative goal. Nevertheless, in some particular clinical settings, such as oligometastatic patients and/or those with a long life expectancy, spinal SBRT could be considered a valid therapeutic option to obtain long-lasting palliation and, when possible, with a curative goal. This review aims to summarize available clinical and dosimetric data of published studies about spinal SBRT.

medicine.medical_specialtyPalliative careStereotactic body radiation therapymedicine.medical_treatment2720 HematologyBone Neoplasms610 Medicine & healthClinical settingsRadiosurgeryRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDosimetryFractures CompressionPalliative radiotherapymedicineHumansSBRTSpinal NeoplasmsToxicitySpine metastasesbusiness.industryPalliative CareCompressionCancerRadiotherapy DosageHematologymedicine.disease10044 Clinic for Radiation OncologySurgeryTreatment OutcomeOncologyLocal controlDosimetry; Local control; Palliative radiotherapy; SBRT; Spine metastases; Toxicity; Bone Neoplasms; Evidence-Based Practice; Fractures Compression; Humans; Palliative Care; Radiotherapy Dosage; Spinal Fractures; Spinal Neoplasms; Treatment Outcome; Radiosurgery; Hematology; Oncology; Geriatrics and GerontologyEvidence-Based Practice030220 oncology & carcinogenesisSpinal Fractures2730 OncologySecondary tumorsGeriatrics and GerontologySpinal metastasesbusinessFracturesStereotactic body radiotherapyCritical Reviews in Oncology/Hematology
researchProduct

Cachexia induces head and neck changes in locally advanced oropharyngeal carcinoma during definitive cisplatin and image-guided volumetric-modulated …

2015

Cancer cachexia is a syndrome characterized by weight loss (WL) and sarcopenia. Aim of the study was to assess the impact of cachexia on head and neck changes during definitive cisplatin and image-guided volumetric-modulated arc radiation therapy in a series of locally advanced oropharyngeal cancer.Volume variations of sternocleidomastoid muscle (SCM) were considered as surrogate of muscle changes related to sarcopenia. Two head and neck diameters, encompassing the cranial limits of II and III nodal levels (defined as 'head diameter' and 'neck diameter', respectively), were measured. All parameters were defined retrospectively by means of on-board cone beam computed tomography images at 1-8…

AdultMaleOncologymedicine.medical_specialtyCachexiamedicine.medical_treatmentLocally advancedMedicine (miscellaneous)030218 nuclear medicine & medical imagingCachexia03 medical and health sciences0302 clinical medicineInternal medicineWeight LossCarcinomamedicineHumansskin and connective tissue diseasesAgedCisplatinNutrition and DieteticsArc (protein)business.industryMiddle Agedmedicine.diseaseRadiation therapyOropharyngeal NeoplasmsOropharyngeal Carcinoma030220 oncology & carcinogenesisSarcopeniaFemaleRadiotherapy Intensity-Modulatedsense organsRadiologyCisplatinbusinessHeadNeckmedicine.drugEuropean Journal of Clinical Nutrition
researchProduct

Dose–volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment

2014

Dysphagia remains a side effect influencing the quality of life of patients with head and neck cancer (HNC) after radiotherapy. We evaluated the relationship between planned dose involvement and acute and late dysphagia in patients with HNC treated with intensity-modulated radiation therapy (IMRT), after a recontouring of constrictor muscles (PCs) and the cricopharyngeal muscle (CM).Between December 2011 and December 2013, 56 patients with histologically proven HNC were treated with IMRT or volumetric-modulated arc therapy. The PCs and CM were recontoured. Correlations between acute and late toxicity and dosimetric parameters were evaluated. End points were analysed using univariate logisti…

Malemedicine.medical_specialtySide effectmedicine.medical_treatmentYoung AdultPlanned DoseSwallowingNuclear Medicine and ImagingIntensity-Modulated80 and overotorhinolaryngologic diseasesHumansMedicineRadiology Nuclear Medicine and imagingTomographyAgedRetrospective StudiesAged 80 and overFull PaperAged; Aged 80 and over; Deglutition; Deglutition Disorders; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Laryngeal Muscles; Male; Middle Aged; Quality of Life; Radiotherapy Dosage; Radiotherapy Intensity-Modulated; Retrospective Studies; Tomography X-Ray Computed; Young Adult; Radiology Nuclear Medicine and ImagingRadiotherapybusiness.industryHead and neck cancerRadiotherapy DosageRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseDysphagiaAcute toxicityDeglutitionX-Ray ComputedSurgeryRadiation therapyHead and Neck NeoplasmsQuality of LifeFemaleRadiotherapy Intensity-ModulatedRadiologyLaryngeal Musclesmedicine.symptomTomography X-Ray ComputedDeglutition DisordersRadiologybusinessFollow-Up StudiesThe British Journal of Radiology
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT

2018

Objective:To investigate metabolic parameters as predictive of local response after stereotactic body radiation therapy (SBRT) for liver-oligometastases.Methods:Inclusion criteria of the present re...

medicine.medical_specialtyStereotactic body radiation therapybusiness.industryLiver NeoplasmsHumans; Liver Neoplasms; Retrospective Studies; Treatment Outcome; Fluorodeoxyglucose F18; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiosurgery; Radiology Nuclear Medicine and ImagingGeneral MedicineRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciencesTreatment Outcome0302 clinical medicineFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyNuclear Medicine and Imaging030220 oncology & carcinogenesisHumansMedicineRadiology Nuclear Medicine and imagingFdg pet ctRadiologyRadiopharmaceuticalsRadiologybusinessRetrospective StudiesThe British Journal of Radiology
researchProduct

[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile a…

2010

[11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific…

OncologyMaleCancer Researchmedicine.medical_treatment[11C]choline-PET tomotherapy prostate relapse lymph node030218 nuclear medicine & medical imagingCholineProstate cancer0302 clinical medicineProstateCarbon RadioisotopesTomographyLymph nodeAdjuvantPelvic NeoplasmsrelapseprostateGeneral MedicineAlkylatingmedicine.anatomical_structureTreatment OutcomeLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesis[11C]choline-PETEstramustineAged; Antineoplastic Agents Alkylating; Antineoplastic Agents Hormonal; Carbon Radioisotopes; Chemotherapy Adjuvant; Choline; Estramustine; Humans; Male; Neoplasm Recurrence Local; Pelvic Neoplasms; Prostatic Neoplasms; Radiotherapy Adjuvant; Treatment Outcome; Positron-Emission Tomography; Tomography Spiral ComputedEstramustinemedicine.drugmedicine.medical_specialtyAntineoplastic Agents HormonaltomotherapyAntineoplastic AgentsTomotherapy03 medical and health sciencesInternal medicinemedicinelymphChemotherapyHumansAntineoplastic Agents AlkylatingAgedChemotherapyHormonalRadiotherapybusiness.industryProstatic Neoplasmsmedicine.diseaseRadiation therapyNeoplasm RecurrenceConcomitantPositron-Emission TomographySpiral ComputedRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessTomography Spiral Computed
researchProduct

Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly…

2016

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 mo…

Simultaneous integrated boostMalemedicine.medical_specialtyCancer ResearchBrachytherapyUterine Cervical NeoplasmsVMATelderly patients030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineWeekly cisplatinmedicineArc therapyHumansAgedCervical cancerRadical treatmentAged 80 and overbusiness.industryRadiotherapy DosageArticlesmedicine.diseaseVolumetric modulated arc therapyCombined Modality TherapySurgeryOncology030220 oncology & carcinogenesisCarcinoma Squamous CellVMAT; advanced cervical cancer; elderly patients; gynecological malignanciesFemaleadvanced cervical cancer; elderly patients; gynecological malignancies; VMAT; Oncology; Cancer ResearchRadiologyDose Fractionation RadiationLymph NodesRadiotherapy Intensity-ModulatedCisplatinbusinessgynecological malignanciesadvanced cervical cancer
researchProduct

In Regard to Chung et al

2015

Cancer ResearchRadiationOncologybusiness.industryTerminology as Topicmedicine.medical_treatmentmedicineHumansRadiology Nuclear Medicine and imagingRadiosurgerybusinessNuclear medicineRadiosurgeryInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose-volume anal…

2015

Background The purpose of this study was to assess predictors of mucositis in oropharyngeal and oral cavity cancer after definitive or adjuvant volumetric modulated arc radiotherapy (VMAT) +/− chemotherapy. Methods Fifty patients were evaluated. Statistical analysis was performed for the following parameters as potential predictors of mucositis ≥ G2: total oral mucosa and oral mucosa minus target high-low radiation dose regions (planning target volumes [PTVs]), mean dose (Dmean), maximum dose (Dmax), chemotherapy, weight loss, and dysphagia. Results Mucositis ≥ G2 was found to be statistically related to chemotherapy, weight loss, dysphagia ≥ G2, total oral mucosa Dmean ≥50 Gy and Dmax ≥65 …

Chemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerOral cavitymedicine.diseaseDysphagia030218 nuclear medicine & medical imagingSurgeryRadiation therapy03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureOtorhinolaryngologyWeight loss030220 oncology & carcinogenesisMucositisMedicinemedicine.symptomOral mucosabusinessNuclear medicineHead & Neck
researchProduct

Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for…

2017

medicine.medical_specialtybusiness.industryUrologymedicine.medical_treatment030218 nuclear medicine & medical imagingSurgeryFunctional imagingRadiation therapy03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesismedicineRadiologybusinessLymph nodeEuropean Urology
researchProduct

Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary to…

2015

To investigate the feasibility and tolerance in the use of adjuvant intensity modulated radiation therapy (IMRT) and simultaneous integrated boost in patients with a diagnosis of breast cancer after breast-conserving surgery.Between September 2011 to February 2013, 112 women with a diagnosis of early breast cancer (T1-2, N0-1, M0) were treated with IMRT and simultaneous integrated boost after breast-conserving surgery in our institution. A dose of 50Gy in 25 fractions was prescribed to the whole breast and an additional dose of radiation was prescribed on the tumour bed. A dose prescription of 60Gy in 25 fractions to the tumour bed was used in patients with negative margins after surgery, w…

Oncologymedicine.medical_treatmentSegmentalMastectomy SegmentalSeverity of Illness IndexBreast cancerNuclear Medicine and ImagingDuctalIntensity-Modulated80 and overBreastMastectomyAdjuvantEarly breast cancerAged 80 and overCarcinoma Ductal BreastSIBRadiotherapy DosageMiddle AgedOncologyBreast cancer; IMRT; SIB; Toxicity; Adult; Aged; Aged 80 and over; Breast Neoplasms; Carcinoma Ductal Breast; Carcinoma Lobular; Esthetics; Feasibility Studies; Female; Follow-Up Studies; Humans; Mastectomy Segmental; Middle Aged; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Adjuvant; Severity of Illness Index; Radiotherapy Intensity-Modulated; Oncology; Radiology Nuclear Medicine and ImagingToxicityFemaleRadiologyRadiodermatitisRadiologyAdjuvantSimultaneous integrated boostAdultmedicine.medical_specialtyEstheticsBreast NeoplasmsLobularBreast cancerInternal medicineSeverity of illnessmedicineHumansRadiology Nuclear Medicine and imagingIMRTAgedToxicityRadiotherapybusiness.industryCarcinomaIntensity-modulated radiation therapymedicine.diseaseAcute toxicityBreast cancer; IMRT; SIB; Toxicity; Oncology; Radiology Nuclear Medicine and ImagingCarcinoma LobularFeasibility StudiesRadiotherapy AdjuvantRadiotherapy Intensity-ModulatedbusinessFollow-Up Studies
researchProduct

Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies

2015

Patients affected with intra-thoracic recurrences of primary or secondary lung malignancies after a first course of definitive radiotherapy have limited therapeutic options, and they are often treated with a palliative intent. Re-irradiation with stereotactic ablative radiotherapy (SABR) represents an appealing approach, due to the optimized dose distribution that allows for high-dose delivery with better sparing of organs at risk. This strategy has the goal of long-term control and even cure. Aim of this review is to report and discuss published data on re-irradiation with SABR in terms of efficacy and toxicity. Results indicate that thoracic re-irradiation may offer satisfactory disease c…

ThoraxRe-Irradiationmedicine.medical_specialtyLung NeoplasmsStereotactic body radiotherapymedicine.medical_treatmentLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapseLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapse; Humans; Lung Neoplasms; Patient Selection; Radiotherapy Dosage; Thorax; Radiosurgery; Oncology; Radiology Nuclear Medicine and ImagingSABR volatility modelRadiosurgeryRadiosurgeryNuclear Medicine and ImagingAblative casemedicineHumansRadiology Nuclear Medicine and imagingLung cancerThoracic relapsebusiness.industryPatient SelectionRetrospective cohort studyRadiotherapy DosageGeneral MedicineThoraxmedicine.diseaseRadiation therapyOncologyRe-irradiationRadiologyStereotactic ablative radiotherapyLung cancerbusinessRadiology
researchProduct

Inflammatory Pseudotumor of Mediastinum Treated with Tomotherapy and Monitored with FDG-PET/CT: Case Report and Literature Review

2010

Mediastinal inflammatory pseudotumor is a rare disease with reactive pseudoneoplastic features and a proven capacity for local invasion. The radiographic appearance of inflammatory pseudotumor is quite non-specific and the definitive diagnosis is based on the histological evaluation of tissue specimens. Resection of the lesion is the treatment of choice. However, nonsurgical treatments such as radiotherapy and steroids have been employed in the setting of incomplete surgical resection, tumor recurrence, and patients being unfit for surgery. The case described here is being reported because of the rare mediastinal location and atypical treatment approach including salvage irradiation and mon…

AdultCancer Researchmedicine.medical_specialtyPET/CTRadiographymedicine.medical_treatmenttomotherapyAdult; Granuloma Plasma Cell; Humans; Mediastinal Neoplasms; Positron-Emission Tomography; Tomography X-Ray Computed; Fluorodeoxyglucose F18; RadiopharmaceuticalsMediastinal NeoplasmsGranuloma Plasma CellTomotherapy030218 nuclear medicine & medical imagingInflammatory pseudotumorLesion03 medical and health sciences0302 clinical medicineFluorodeoxyglucose F18HumansMedicineTomographyPET-CTGranulomabusiness.industryMediastinumGeneral MedicinemediastinumX-Ray ComputedRadiation therapymedicine.anatomical_structureOncologyPositron-Emission TomographyPlasma CellInflammatory pseudotumorRadiologyRadiopharmaceuticalsmedicine.symptomTomography X-Ray Computedbusiness030217 neurology & neurosurgeryRare diseaseTumori Journal
researchProduct

Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study.

2019

Objective: To report preliminary findings of a phase II study exploring the clinical outcomes of moderate hypofractionated radiotherapy performed with helical tomotherapy (HT) using computed tomography–magnetic resonance imaging–based planning for localized prostate cancer. Methods: The phase II prospective study received ethics approval from our institutional ethics committee. A dose of 60 Gy/20 fractions for low–intermediate risk prostate cancer by means of HT was explored. Primary endpoints of the study were acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. Secondary endpoints were quality of life and biochemical-free survival. Results: A total of 35 patients were i…

Hypofractionated RadiotherapyMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmenttomotherapyPhases of clinical researchTomotherapy030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicinePreliminary reportProstatemedicineBiomarkers TumorHumansProspective StudiesNeoplasm MetastasisProspective cohort studyRadiometryProstate hypofractionation tomotherapyAgedNeoplasm StagingAged 80 and overhypofractionationbusiness.industryRadiotherapy Planning Computer-AssistedProstateProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasehypofractionation; Prostate; tomotherapymedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisQuality of LifeObservational studyRadiation Dose HypofractionationRadiologyRadiotherapy Intensity-ModulatedbusinessFollow-Up StudiesTumori
researchProduct

Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study

2017

Abstract Introduction Aim of the present study is to evaluate homolateral and contralateral hippocampus (H-H, C-H, respectively) dose during Fractionated Stereotactic Radiotherapy (FSRT) or Radiosurgery (SRS) for brain metastases (BM). Materials & methods Patients with BM   3 months, were considered for SRS/FSRT (total dose 15–30 Gy, 1–5 fractions). For each BM, a Flattening Filter Free (FFF) Volumetric Modulated Arc Therapy (VMAT) plan was generated with one or two arcs. Hippocampi were not considered during optimizations phase and were contoured and evaluated retrospectively in terms of dose: the Dmedian, Dmean, D0.1cc and the V1Gy, V2Gy, V5Gy and V10Gy were analyzed. Results From April 2…

AdultMalemedicine.medical_treatmentBiophysicsGeneral Physics and AstronomyStereotactic fractionatedHippocampal formationRadiation DosageRadiosurgeryHippocampusRadiosurgery030218 nuclear medicine & medical imagingStereotactic radiotherapyYoung AdultPhysics and Astronomy (all)03 medical and health sciences0302 clinical medicineNuclear Medicine and ImagingStereotactic radiotherapymedicineHumansRadiology Nuclear Medicine and imagingIn patientHippocampiAgedAged 80 and overRadiotherapyBrain Neoplasmsbusiness.industryRadiotherapy DosageBrain metastasesGeneral MedicineMiddle AgedBrain metastases; Hippocampi; Radiotherapy; Stereotactic fractionated; Stereotactic radiotherapy; Biophysics; Radiology Nuclear Medicine and Imaging; Physics and Astronomy (all)Volumetric modulated arc therapyRadiation therapy030220 oncology & carcinogenesisTotal doseFemaleDose reductionParticle AcceleratorsRadiologybusinessNuclear medicinePhysica Medica
researchProduct

The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)

2017

GynecologyOncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicinemedicineRetrospective cohort studyHematologymedicine.diseasebusinessER2-positive (HER2+ve) breast cancer (BC) brain metastases (BMs)
researchProduct

Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.

2016

Purpose To evaluate the influence of radiation dose on tumor regression grade (TRG) and sphincter preservation rate in a series of cT3N0-1 rectal cancer patients treated with neoadjuvant chemoradiotherapy (CT-RT) with or without a sequential radiation boost. Materials and methods Between May 2002 and September 2013, 116 cases were eligible for retrospective evaluation. Radiotherapy was delivered for a total dose of 45 Gy (no boost arm) or 50.4 Gy (boost arm). TRG was evaluated with the Dworak scale. Results Median follow-up was 62 months (range, 12-138 months). The 5-year overall survival and local control rates were 72% and 93%, respectively. Fifty-five patients (47%) were treated with a s…

MaleCancer ResearchTime FactorsTumor downsizingColorectal cancermedicine.medical_treatmentAnal CanalKaplan-Meier EstimateSingle Center030218 nuclear medicine & medical imaging0302 clinical medicineAdjuvantNeoadjuvant therapyDigestive System Surgical ProceduresTumor Regression GradeIleostomyMedicine (all)Colorectal cancer; Radiation therapy; Tumor downsizing; Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Tract; Humans; Ileostomy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Adjuvant; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle AgedNeoadjuvant TherapyRadiation therapyTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologyFluorouracilmedicine.drugAdultmedicine.medical_specialtyUrogenital SystemAntineoplastic AgentsAdenocarcinomaCapecitabine03 medical and health sciencesmedicineHumansCapecitabineAgedNeoplasm StagingRetrospective StudiesRadiotherapybusiness.industryRectal Neoplasmsmedicine.diseaseColorectal cancerRadiation therapyGastrointestinal TractConcomitantRadiotherapy AdjuvantbusinessOrgan Sparing TreatmentsChemoradiotherapyFollow-Up StudiesTumori
researchProduct

Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy

2015

INTRODUCTION Aim of the study is to evaluate the impact of Cho-PET/CT in decision-making strategy of patients with localized prostate cancer (PC) eligible to definitive radiotherapy (RT). MATERIALS AND METHODS Sixty patients Cho-PET/CT before RT were prospectively enrolled. All patients were treated with volumetric modulated arc therapy with simultaneous integrated boost in 28 fractions. Androgen deprivation therapy was prescribed according to National Comprehensive Cancer Network (NCCN) risk classification. Therapeutic strategy based on the Cho-PET/CT evaluation was compared with the strategy that would have been proposed in case of PET not available and/or not strictly indicated, accordin…

Malemedicine.medical_specialtyRadical treatmentmedicine.medical_treatmentClinical Decision-Making18F-cholineMultimodal ImagingCholineAndrogen deprivation therapyProstate cancerProstateNuclear Medicine and ImagingIntensity-ModulatedMedicineHumansRadiology Nuclear Medicine and imagingRadiation treatment planningTomographyAgedPET-CTProstate cancerRadiotherapybusiness.industryCancerProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseX-Ray ComputedRadiation therapymedicine.anatomical_structurePositron-Emission TomographyRadiologyCho-PET/CT; Prostate cancer; Radical treatment; Radiotherapy; Aged; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Prostatic Neoplasms; Radiopharmaceuticals; Clinical Decision-Making; Positron-Emission Tomography; Radiotherapy Intensity-Modulated; Tomography X-Ray Computed; Radiology Nuclear Medicine and ImagingRadiotherapy Intensity-ModulatedRadiopharmaceuticalsbusinessNuclear medicineRadiologyTomography X-Ray ComputedCho-PET/CT
researchProduct

Infrared-guided patient setup for breast cancer patients: Comparison with CBCT

2016

medicine.medical_specialtyBreast cancerbusiness.industryBiophysicsGeneral Physics and AstronomyMedicineRadiology Nuclear Medicine and imagingGeneral MedicineRadiologybusinessmedicine.diseasePhysica Medica
researchProduct

Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center expe…

2018

Background: Several experiences in the literature report SBRT as an effective treatment option for medically inoperable early stage non-small cell lung cancer (NSCLC) and oligometastatic disease. The optimal fractionation schedules and total dose remain controversial. In this study, we evaluated the safety in terms of toxicity and efficacy of using of 8–10 fractions schedules with Helical Tomotherapy (HT) for primary and metastatic lung lesions. Methods: Between March 2014 and May 2016, a total of 39 patients (median age 72 years, range 26–91) were treated with HT-SBRT for malignant lung lesions: 22 patients with early stage NSCLC, 17 with oligometastases. Patients received 8–10 fract…

AdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentStereotactic radiation therapyRadiosurgerySingle CenterTomotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineHelical tomotherapyCarcinoma Non-Small-Cell LungmedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Lung cancerAgedPneumonitisAged 80 and overSBRTHelical tomotherapy; Lung cancer; Radiotherapy; SBRTRadiotherapybusiness.industryRadiotherapy DosageGeneral MedicineMiddle Agedmedicine.diseaseSurvival RateRadiation therapyTreatment Outcome030220 oncology & carcinogenesisFeasibility StudiesFemaleDose Fractionation RadiationRadiologyLung cancerbusinessTomography Spiral ComputedEsophagitis
researchProduct

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

2014

The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.

Malemedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyProstate cancermedicineEffective treatmentHumansMedical physicsDose FractionationSalvage brachytherapySalvage TherapyProstate cancerbusiness.industryRadiobiologyProstatic NeoplasmsRadiotherapy DosageHDR-BTHematologymedicine.diseaseBrachytherapy boost; HDR-BT; High-dose rate brachytherapy; Prostate cancer; Radiobiology; Salvage brachytherapy; Dose Fractionation; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Brachytherapy; Radiotherapy Dosage; Hematology; Oncology; Geriatrics and GerontologyHigh-Dose Rate BrachytherapyBrachytherapy boostTreatment OutcomeOncologyRadiologyDose Fractionation RadiationGeriatrics and GerontologybusinessHigh-dose rate brachytherapySalvage brachytherapyCritical reviews in oncology/hematology
researchProduct

Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response

2016

To analyze lung lesion volume variations by contouring on cone-beam CT (CBCT) images to evaluate the early predictive parameters of stereotactic ablative radiation therapy (SABR) treatment response.The prescribed dose of SABR was varied according to the tumour site (central or peripheral) and maximum diameter of the lesions by using a strategy of risk-adapted dose prescription with a dose range between 48 and 70 Gy in 3-10 consecutive fractions. For the purpose of the analysis, the gross tumour volume (GTV) was recontoured for each patient at first and last CBCT using two lung levels/windows: (a) -600/1000 HU and (b) -1000/250 HU. Univariate analysis was performed to evaluate a correlation …

ContouringCone beam computed tomographyUnivariate analysismedicine.medical_specialtyLungFull Paperbusiness.industrymedicine.medical_treatmentGeneral MedicineSABR volatility modelEffective dose (radiation)030218 nuclear medicine & medical imagingRadiation therapy03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureNuclear Medicine and Imaging030220 oncology & carcinogenesisAblative caseMedicineRadiology Nuclear Medicine and imagingRadiologyRadiologyNuclear medicinebusinessThe British Journal of Radiology
researchProduct

A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer:…

2021

PURPOSE/OBJECTIVE(S): stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases still remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate how lung SBRT can impact on the progression to the polymetastatic disease (PMD). MATERIALS/METHODS: the study involved 22 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1023 lung metastases treated with SBRT in 622 patients were reported. The median BED was 105 Gy10. Lesion diameter GTV, PTV volume, dose, fractionations, and site…

Cancer ResearchUnivariate analysismedicine.medical_specialtyRadiationPredictive markerColorectal cancerbusiness.industrymedicine.medical_treatmentmedicine.disease_causemedicine.diseaseSABR volatility modelPrimary tumorRadiation therapyLesioncolorectal metastaseOncologymedicineRadiology Nuclear Medicine and imagingKRASRadiologyoligometastasemedicine.symptombusinessSABRInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Fe…

2017

The aim of this study was to evaluate the acute toxicity profiles of a moderate hypofractionated regimen with volumetric modulated arc therapy (VMAT) in patients with prostate cancer (PC) who underwent radical prostatectomy.From December 2012 to February 2016, 125 patients, previously having undergone radical prostatectomy, received adjuvant (64 patients) or salvage (61 patients) radiotherapy (RT) inside an institutional protocol of moderate hypofractionation schedule using the VMAT technique (Varian RapidArc, Palo Alto, CA). Eligible patients were 85 years old, with an Eastern Cooperative Oncology Group performance status of 0 to 2, histologically proven adenocarcinoma of the prostate with…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyUrinary incontinenceDisease-Free Survival030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancersymbols.namesake0302 clinical medicineInternal medicinemedicineHumansAdjuvantFisher's exact testAgedNeoplasm StagingAged 80 and overProstatectomySalvage TherapyProstate cancerRadiotherapyAdjuvant; Hypofractionation; Prostate cancer; Radiotherapy; Salvage; Oncology; Urologybusiness.industryProstatectomyProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle AgedProstate-Specific Antigenmedicine.diseaseAcute toxicityRadiation therapyRegimenTreatment OutcomeOncology030220 oncology & carcinogenesissymbolsHypofractionationSalvageRadiation Dose HypofractionationRadiotherapy AdjuvantRadiotherapy Intensity-Modulatedmedicine.symptombusinessRadiotherapy Image-GuidedClinical Genitourinary Cancer
researchProduct

Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer.

2018

Aim: Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods: The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabColorectal cancermedicine.medical_treatmentSABR volatility modelRadiosurgery03 medical and health sciences0302 clinical medicineInternal medicineAblative casemedicineHumansAgedRetrospective StudiesLungbusiness.industryGeneral MedicineOxygenationMiddle Agedmedicine.diseaseCombined Modality TherapyRadiation therapyBevacizumab030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic Neoplasmsbusinessmedicine.drugTumori
researchProduct

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

2019

There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database.Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted …

Adult0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSocio-culturaleBreast NeoplasmsLapatinibTreatment experiencedRadiosurgerySRS03 medical and health sciences0302 clinical medicineBreast cancerTrastuzumabInternal medicineHER2 Positive Breast CancerBiomarkers TumormedicineHumansAgedRetrospective Studiesbusiness.industryLapatinibTrastuzumabMiddle AgedWBRTPrognosismedicine.diseaseCombined Modality TherapyConfidence intervalSurvival RateRadiation therapyLapatinib SRS Surgery Trastuzumab WBRT030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisLapatinib; SRS; Surgery; Trastuzumab; WBRTSurgeryFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drugClinical Breast Cancer
researchProduct